Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03276494 · ClinicalTrials.gov registry record · Phase 2

Safety & Tolerability of Hypertonic Saline Administration Via Intraosseous Access

A Phase 2 study of Stroke and Cerebral Edema, sponsored by Ohio State University.

Completed
Registry status
Phase 2
Development phase
6
Enrollment target
1
Study location

NCT03276494 is a Phase 2 study of Stroke and Cerebral Edema that has completed, run by Ohio State University. The registered enrollment target is 6 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03276494, a Phase 2 study of Stroke and Cerebral Edema, has completed, sponsored by Ohio State University.

COMPLETED
Registry status
Phase 2
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

Hypertonic saline is used to treat elevated intracranial pressure. Intraosseous vascular access has been used to administer fluids and medications. This study combines these to administer 3% hypertonic saline via IO.

Interventions

  • DRUG Hypertonic saline
  • DEVICE Intraosseous

Study Locations (1)

Ohio

  • The Ohio State University - Columbus

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2017-04-21
Est. Completion 2018-04-21
Phase Phase 2

Sponsor

Ohio State University

552 total trials

What the Registry Record Tells You About NCT03276494

The ClinicalTrials.gov registry entry for NCT03276494 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Stroke appearing as the primary indexed condition, and to 2 interventions - of which Hypertonic saline is the first listed.

NCT03276494 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT03276494 about?

NCT03276494 is a clinical study titled "Safety & Tolerability of Hypertonic Saline Administration Via Intraosseous Access". Hypertonic saline is used to treat elevated intracranial pressure. Intraosseous vascular access has been used to administer fluids and medications. This study combines these to administer 3% hypertonic saline via IO.

What is the current status of trial NCT03276494?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2017-04-21. Estimated completion is 2018-04-21.

What conditions does trial NCT03276494 study?

This clinical trial studies the following conditions: Stroke, Cerebral Edema, Intracranial Hypotension.

What interventions are being tested in trial NCT03276494?

The interventions under investigation include: Hypertonic saline (DRUG), Intraosseous (DEVICE).

Who is sponsoring clinical trial NCT03276494?

This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03276494 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.